RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases

Graham Casey, Phillippa J. Neville, Sarah J. Plummer, Ying Xiang, Lisa M. Krumroy, Eric A. Klein, William J. Catalona, Nina Nupponen, John D. Carpten, Jeffrey M. Trent, Robert H. Silverman, John S. Witte

Research output: Contribution to journalArticle

Abstract

RNASEL (encoding ribonuclease L) has recently been proposed as a candidate for the hereditary prostate cancer (HPC1) gene. We determined that the RNASEL variant Arg462Gln has three times less enzymatic activity than the wildtype and is significantly associated with prostate cancer risk (P = 0.007). At least one copy of the mutated allele that causes this substitution is carried by nearly 60% of the men in our study. Men that are heterozygous with respect to the mutated allele have 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the risk.

Original languageEnglish (US)
Pages (from-to)581-583
Number of pages3
JournalNature genetics
Volume32
Issue number4
DOIs
StatePublished - Dec 1 2002

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases'. Together they form a unique fingerprint.

  • Cite this

    Casey, G., Neville, P. J., Plummer, S. J., Xiang, Y., Krumroy, L. M., Klein, E. A., Catalona, W. J., Nupponen, N., Carpten, J. D., Trent, J. M., Silverman, R. H., & Witte, J. S. (2002). RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature genetics, 32(4), 581-583. https://doi.org/10.1038/ng1021